Biotech World

The latest news about the biotech and pharmaceutical industy.

[Biotech World @BiotechWorld]

AstraZeneca, Daiichi unpack Dato-DXd's overall survival fail ahead of FDA decision https://t.co/ZaTfOF7X8l

[Biotech World @BiotechWorld]

Boehringer and Bayer's oral meds deliver in early HER-2 mutant lung cancer studies https://t.co/ZHPp0vzgf4

[Biotech World @BiotechWorld]

MBX aims for $136M IPO to take potential rival to Ascendis' Yorvipath into phase 3 https://t.co/s1s6WDGOqs

[Biotech World @BiotechWorld]

Merck, Daiichi repeat early success in small cell lung cancer with updated ADC data https://t.co/Bapl01MwGa

[Biotech World @BiotechWorld]

Tern’s oral GLP-1 shows 5% weight loss at 1 month at highest dose https://t.co/oeeLnNrNfu

[Biotech World @BiotechWorld]

GSK's long-acting asthma drug halved attacks in phase 3, backing up blockbuster hopes https://t.co/pxtsBK6MSh

[Biotech World @BiotechWorld]

Relay races toward pivotal trial as breast cancer data tee up clash with AstraZeneca's Truqap https://t.co/rVWjMXbq5o

[Biotech World @BiotechWorld]

Lilly-backed Superluminal raises $120M series A to bring membrane receptor drugs into the clinic https://t.co/VyMY8HQEVe

[Biotech World @BiotechWorld]

With $370M debut, Candid Therapeutics is upfront about goal to lead a coming T-cell engager wave https://t.co/Z7XaW6OXqr

[Biotech World @BiotechWorld]

AstraZeneca execs 'not worried' after IL-33 drug fails to improve COPD breathing in phase 2 https://t.co/Ebfcw76VoF

[Biotech World @BiotechWorld]

AstraZeneca outlines AI-enabled TROP2 biomarker strategy for Daiichi ADC after limited lung cancer showing https://t.co/f1cM5RfuEY

[Biotech World @BiotechWorld]

FDA concerned Iterum’s urinary tract infection drug could cause antimicrobial resistance https://t.co/cX0Aw6wrMf

[Biotech World @BiotechWorld]

Psyence pays $500k to acquire fellow psilocybin biotech Clairvoyant and phase 2 AUD asset https://t.co/Na3ldjKhb8

[Biotech World @BiotechWorld]

Zenas, Bicara set out to raise $180M+ in separate IPOs to fund autoimmune, cancer prospects https://t.co/nKFcKdIagJ

[Biotech World @BiotechWorld]

Chutes & Ladders—BMS vet answers Foghorn's call for CBO https://t.co/x75JZXY5Yf

[Biotech World @BiotechWorld]

Connect reduces China workforce, mulls strategy for potential Dupixent rival https://t.co/XmvSO6CYLS

[Biotech World @BiotechWorld]

Crestone's antibiotic cures C. diff infections and prevents recurrence better than vancomycin in phase 2 https://t.co/m0PHuAPegf

[Biotech World @BiotechWorld]

Lykos CEO steps down, the latest move in a string of chaotic changes https://t.co/TmzTxyMNsd

[Biotech World @BiotechWorld]

Astellas unveils Massachusetts lab that will be shared with biotechs, academia researchers https://t.co/UE3CDdnri0

[Biotech World @BiotechWorld]

Gene therapy biotech Medera looks back to SPAC as way to go public https://t.co/SkmMxBnpiJ